Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Completed Initiated Jan 18, 2024 (3 years ago)

Febuxostat Tablets 40mg

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: Microbial contamination was reported in stagnant water in the duct of the manufacturing equipment.

Cause type: Microbial contamination

Bacteria, mold, yeast or other microorganisms detected in the product. Contamination can occur from water systems, equipment or handling, and can cause infection. All microbial contamination recalls.

What was recalled

Febuxostat Tablets 40mg, Rx Only, 30 Tablets per bottle, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, Manufactured by: Sun Pharmaceutical Industries Ltd., Survey No. 259/15, Dadra-396 191 (U.T. of D & NH), INDIA, NDC 47335-721-83.

Affected NDC 47335-0721-83

Compare with the code on your package — it is the most precise check available.

Drug: Febuxostat

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Febuxostat
NDC 47335-0721
40 mg/1 Tablet, Film Coated
Oral
Sun Pharmaceutical Industries, Inc. Rx
Recalling firm
Sun Pharmaceutical Industries INC
NDC code
47335-721-83
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0264-2024 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now completed, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Febuxostat recalls

See all
Class II · Moderate risk

Febuxostat Tablets 80mg

CGMP Deviations: Microbial contamination was reported in stagnant water in the duct of the manufacturing equipment.

Ongoing Microbial contamination Sun Pharmaceutical Industries INC NDC 16714-060-01 D-0369-2024
Class II · Moderate risk

Febuxostat Tablets 40mg

CGMP Deviations: Microbial contamination was reported in stagnant water in the duct of the manufacturing equipment.

Ongoing Microbial contamination Sun Pharmaceutical Industries INC NDC 16714-059-01 D-0368-2024
Class II · Moderate risk

Febuxostat Tablets 80 mg

CGMP Deviations: Microbial contamination was reported in stagnant water in the duct of the manufacturing equipment.

Completed Microbial contamination Sun Pharmaceutical Industries INC NDC 47335-722-83 D-0265-2024
Class II · Moderate risk

FEBUXOSTAT Tablet

Labeling: Label Mixup; FEBUXOSTAT Tablet, 40 mg may be potentially mislabeled as methylPREDNISolone, Tablet, 4 mg, NDC 59746000103, Pedigree: AD21811_17, EXP: 5/1/2014; tiZANidine HCl, Tablet, 2 mg, NDC 55111017915, Pedigree: W002663, EXP: 6/5/2014; SODIUM CHLORIDE, Tablet, 1000 mg, NDC 00527111610, Pedigree: W003926, EXP: 7/1/2014.

Terminated Labeling / mix-up Aidapak Services, LLC D-698-2014

Other recalls by Sun Pharmaceutical Industries INC

All 2024 recalls
Class II · Moderate risk

Carbamazepine Tablets

CGMP Deviations; black spots found on tablets from burnt excipient during manufacturing

Ongoing cGMP deviation Sun Pharmaceutical Industries INC NDC 51672-4005-3 D-0770-2026
Class II · Moderate risk

Perampanel CIII Tablets

Labeling: Label Mix-up: 10mg Perampanel CIII tablet was found in a Perampanel CIII bottle labeled Perampanel 6 mg tablets.

Ongoing Labeling / mix-up Sun Pharmaceutical Industries INC NDC 51672-4206-6 D-0628-2026